Recursion announced the public release of MolRec™ - one of its many interactive internal tools to explore the company's proprietary maps of biology and chemistry. Just as a regular map is a navigation tool in the physical world, Recursion's maps are designed to help scientists understand the topology and connectedness of human biology and chemistry to navigate the path to new medicines more efficiently. In addition, Recursion released RxRx3, its larger open-source cellular imaging dataset to date, spanning approximately 2.2 million images across the human genome and 1,600 commercially available compounds in a single cell type.

Recursion's maps are constructed using high-dimensional datasets generated in-house in the company's highly automated and industrialized laboratories. The foundational dataset uses a technique known as phenomics, in which machine learning algorithms extract structured data from billions of images of human cells that have been manipulated by genome-wide CRISPR-Cas9 knockouts, chemical compounds, or other reagents. Digital representations of cells are compared and contrasted to predict trillions of relationships across biology and chemistry — even without physically testing all of the possible combinations.

To date, Recursion has generated more than 3 trillion searchable gene and compound relationships across all of its maps that are used to identify novel insights and advance new therapeutic programs, unconstrained by human bias or existing scientific literature. The RxRx3 dataset and the part of MolRec™ available to the public are built using a small subset of Recursion's experimental inputs: Approximately 1,600 commercially-available compounds at eight doses each and 17,000 gene knockouts. The majority of genes are anonymized in the dataset, enabling people to explore and learn from this massive dataset while protecting Recursion's business interests.

The application can be used to uncover known and novel compound-compound as well as compound-gene relationships. Importantly, MolRec™ provides information on a compound's potency and insight into its potential mechanism of action. Many of the insights found within MolRec™ have not been documented in scientific literature.

The MolRec™? app and the corresponding dataset, RxRx3, were released during Recursion's Download Day, the company's first R&D Day. Sell-side equity research analysts, institutional investors, and investment bankers joined members of Recursion's executive team and board of directors for an engaging, in-person event at the company's headquarters in Salt Lake City, Utah.

The day consisted of presentations on Recursion's technology, science, pipeline and partnerships, as well as demonstrations of Recursion's mapping and navigating technology and tours of the company's highly automated laboratories.